Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.57 |
| ▸ | AKT1 | P31749 | 6/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.45 |
| ▸ | XIAP | P98170 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644467 | 1.00 | NOTUM (0.57) | NOTUMAKT1ROCK2ROCK1BIRC2 | |
| SCHEMBL9047131 | 0.88 | NOTUM (0.53) | NOTUMAKT1ROCK2ROCK1BIRC2 | |
| SCHEMBL6543796 | 0.86 | NOTUM (0.54) | NOTUMAKT1ROCK2ROCK1BIRC2 | |
| SCHEMBL1572534 | 0.86 | NOTUM (0.63) | NOTUMAKT1ROCK2ROCK1HDAC1 | |
| SCHEMBL30232786 | 0.86 | NOTUM (0.63) | NOTUMAKT1ROCK2ROCK1HDAC1 | |
| SCHEMBL655024 | 0.85 | NOTUM (0.80) | NOTUMAKT1ROCK2ROCK1HDAC1 | |
| SCHEMBL6543487 | 0.84 | NOTUM (0.55) | NOTUMAKT1ROCK2ROCK1HDAC1 | |
| SCHEMBL1713780 | 0.84 | NOTUM (0.57) | NOTUMAKT1ROCK2ROCK1BIRC2 | |
| Hydrochloric Acid SCHEMBL2257588 | 0.83 | NOTUM (0.78) | NOTUMAKT1ROCK2ROCK1HDAC1 | |
| SCHEMBL6543320 | 0.81 | NOTUM (0.57) | NOTUMAKT1ROCK2ROCK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-11-04 | — | — | US | claimed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | claimed |
| US-6291672-B1 | FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION | SANOFI-SYNTHELABO (FR) | 2001-09-18 | — | — | US | claimed |
| CN-114591327-B | Indoline piperidine urea TRPV1 antagonism and MOR agonism double-target-point medicine, preparation method and application | 河南大学 | 2023-02-07 | — | — | CN | disclosed |
| CN-114591327-A | Indoline piperidine urea type TRPV1 antagonistic and MOR agonistic double-target-point medicine, preparation method and application | 河南大学 | 2022-06-07 | — | — | CN | disclosed |
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-11-04 | — | — | US | disclosed |
| US-6710042-B2 | PIPERIDINE DERIVATIVES; TREATMENT OF PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-03-23 | — | — | US | disclosed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | disclosed |
| US-6291672-B1 | FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION | SANOFI-SYNTHELABO (FR) | 2001-09-18 | — | — | US | disclosed |
| US-6028082-A | FOR TRATING PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | NOTUM 4655/4885AKT1 4106/4885ROCK2 3416/4885 |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | NOTUM 4655/4885AKT1 4106/4885ROCK2 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.